NCT07591753Completed
Long-Term Safety and Effectiveness of Mepolizumab 300 mg in Europe (Mepo LTF Study)
Assessing The Long-Term Effectiveness and Safety of Mepolizumab 300mg/Month in the European Real-Life Setting (Mepo Long-term Study)
Source: ClinicalTrials.gov · Last updated 27 Oct 2026
Brief summary (registry, in English)
This observational study aims to evaluate the long-term effectiveness and safety of mepolizumab 300 mg/4 weeks in adults with eosinophilic granulomatosis with polyangiitis (EGPA) in the European real-life setting. The main questions it aims to answer are: * How effective is mepolizumab 300 mg/4 weeks over long-term follow-up in patients with EGPA? * How safe is mepolizumab 300 mg/4 weeks during long-term treatment? * What are the effects of switching mepolizumab dosage from 300 mg/4 weeks to 100 mg/4 weeks, or from 100 mg/4 weeks to 300 mg/4 weeks? Participants already receiving mepolizumab as part of routine clinical practice. Researchers will retrospectively collect demographic, clinical, laboratory, and treatment-related data from medical records. For patients starting mepolizumab 300 mg/4 weeks, data will be collected from treatment initiation and during follow-up up to 60 months. For patients who change mepolizumab dose, data will also be collected at the time of dose switch and 3 months later.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 299 (actual)
- First submitted
- 11 May 2026
- Start date
- 18 Sept 2025
- Primary completion date
- 31 Mar 2026
- Lead sponsor
- European EGPA Study Group
- Diseases
- ANCA-associated vasculitis
- NCT number
- NCT07591753
What you commit to
- Study type: Observational
- Participants enrolled: 299
- From 18 Sept 2025 to the primary completion date, 31 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \- Follow-up shorter than 3 months after mepolizumab initiation or after dose switch.
Who the study is looking for
- Adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). Patients who meet the 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) Classification Criteria for EGPA or the criteria proposed in the MIRRA trial.
- Patients receiving mepolizumab 300 mg/4 weeks, either as the first mepolizumab regimen or after dose escalation from mepolizumab 100 mg/4 weeks.
- Availability of at least 3 months of follow-up data after mepolizumab initiation or after dose switch.
- Written informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Florence Coordinator of this site? Confirm its status | Florence | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.